Lang GE, Stahl A, Voegeler J, et al. - The PRIDE study is the first study intended to test the safety and effectiveness of ranibizumab in patients with proliferative diabetic retinopathy (PDR) but without diabetic macular edema with or without additional panretinal photocoagulation (PRP; current standard of care in PDR) vs PRP monotherapy. In total, 106 PDR individuals without diabetic macular oedema were randomized to receive ranibizumab 0.5 mg monotherapy (n = 35), PRP (n = 35) or combined ranibizumab 0.5 mg/PRP (n = 36). Even in patients without DME, ranibizumab is more effective vs PRP monotherapy in reducing neovascularization (NV) area over a 12-month period and improving visual outcomes in PDR. Long-term follow-up to study patient adherence to anti-VEGF therapy over a longer period of time and to assess NV recurrence rates under ranibizumab monotherapy is warranted.